Aurobindo Pharma Limited (AUROPHARMA.NS) fair value

ACCE thesis

Aurobindo Pharma makes generic oral solids, injectables and antiretroviral drugs, and sells them to regulated markets including the US and Europe, where it competes on cost and regulatory approvals rather than brand. The structural edge is its large portfolio of approved ANDAs and its own API and formulation plants, which keep unit costs low enough to win volume when competitors exit or delay launches. Revenue growth of 16.3% and a 58.9% gross margin point to a mix shift toward higher-value injectables and complex generics, with the 15.2% operating margin showing that the expansion is being reinvested or absorbed by pricing pressure. The stock trades at 25.2x trailing earnings but 17.2x forward, so the market is pricing a meaningful earnings step-up that the next few reporting cycles will either confirm or undercut. Worth a deeper look if the team wants exposure to Indian generics with US pricing and approval-cycle risk as the variables to underwrite.